Business Wire

NETSCOUT Combines Leading Global Threat Intelligence With Machine Learning to Protect Enterprises From Rapidly Spreading Dynamic DDoS Attacks

11.7.2023 13:05:00 EEST | Business Wire | Press release

Share

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT), a leading provider of performance management, cybersecurity, and DDoS attack protection solutions, today released its latest version of Arbor Edge Defense (AED) which includes new ML-based Adaptive DDoS Protection.

According to NETSCOUT's latest DDoS Threat Intelligence Report, there has been a significant increase in a new breed of dynamic DDoS attacks that use multiple vectors and techniques to launch botnet-based, direct-path, state exhaustion, and application-layer attacks designed to evade conventional static network and cloud-only-based DDoS defense.

Every enterprise is at grave risk today if they don’t deploy an effective DDoS solution on-premises to protect their network edge, internet-facing services, and critical stateful infrastructure such as firewalls and load balancers from these constantly evolving attacks. Attackers can send dynamic direct-path DDoS traffic at any time, and they can quickly change attack vectors during the attack making them nearly impossible to defend without the right technology. With AED’s Adaptive DDoS Protection, IT teams now have a scalable, always-on stateless packet processing solution that uses unmatched visibility into more than 50% of all internet traffic, global, real-time DDoS attack threat intelligence, decades of DDoS mitigation experience, and machine learning (ML) software intelligence to automatically detect, adapt to, and mitigate dynamic DDoS attacks.

“As cyber threats become more sophisticated and dynamic, IT teams need to out-smart bad actors with the ability to adapt and surgically block unwanted traffic at the network edge,” said Scott Iekel-Johnson, AVP, DDoS and Threat Intelligence at NETSCOUT. “With unmatched real-time visibility into global DDoS attack activity and decades of mitigation experience, no one knows more about DDoS attacks than NETSCOUT. With AED’s Adaptive DDoS Protection, enterprises can take advantage of our DDoS attack expertise and minimize unnecessary workloads that force expensive upgrades with an always-on product that can scale to protect every edge from a single pane of glass.”

Automated AED Protects Enterprises from Threats

Deployed at the Internet edge in front of any firewall, AED screens incoming and outgoing traffic using stateless packet processing, global DDoS threat intelligence, and ML to block inbound cyber threats, including DDoS attacks and other bulk malicious traffic. It protects and reduces the load on firewalls, load balancers, or VPN concentrators and stops the proliferation of malware within an organization. AED can also block outbound communications sent from compromised internal devices to sites run by bad actors to prevent data breaches and other malware activity. It contains the threat while giving the IT team time to investigate and remove it before it can cause further damage. In the event of a large volumetric DDoS attack, AED’s cloud signaling feature integrates with cloud DDoS protection providers, including NETSCOUT’s Arbor Cloud, to intelligently and automatically coordinate attack response between cloud-based volumetric protection and on-premise adaptive DDoS attack protection.

Visibility into 50% of All Internet Traffic

NETSCOUT ASERT, the company’s expert security research and DDoS attack mitigation team, works with over 500 Internet Service Providers (ISPs) to maintain a unique sensor network called ATLAS. With over 400 Tbps of international transit traffic received every second of every day from 93 countries, 600 industry verticals, and more than 31,000 autonomous systems, ATLAS provides ASERT with unmatched visibility into more than 50% of all internet traffic and real-time DDoS attack activity. ASERT analyzes the ATLAS data and distributes its findings to the Arbor Edge Defense (AED) solution via the ATLAS Intelligence Feed (AIF). AIF continually arms AED with highly curated intelligence that constantly updates the IP addresses of bots and reflectors/amplifiers actively participating in DDoS attacks around the globe. Created from real-world ASERT mitigation experience, AED’s Adaptive DDoS defense capabilities use ML-based algorithms to automatically recommend changes to attack countermeasures designed to stop dynamic DDoS attacks.

To learn more about how Adaptive DDoS Protection for AED automatically protects networks from dynamic DDoS attacks, visit our website.

About NETSCOUT

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) protects the connected world from cyberattacks and performance and availability disruptions through the company’s unique visibility platform and solutions powered by its pioneering deep packet inspection at scale technology. NETSCOUT serves the world’s largest enterprises, service providers, and public sector organizations. Learn more at www.netscout.com or follow @NETSCOUT on LinkedIn, Twitter, or Facebook.

©2023 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Visibility Without Borders, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Maribel Lopez
Manager, Marketing & Corporate Communications
+1 781 362 4330
maribel.lopez@netscout.com

Chris Shattuck
Finn Partners for NETSCOUT
+1 404 502 6755
NETSCOUT-US@FinnPartners.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye